FINHUB Insights

ABBV · Q1 FY26 · Mar 31, 2026

AbbVie Q1 FY26: where the revenue came from and where it went

AbbVie Q1 FY26: revenue $15B (+12% year over year). Net profit $0.7B. Largest cohort Skyrizi $4.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 8, 2026 10-Q
Sankey diagram of AbbVie's income statement for Q1 FY26: revenue of $15 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$15B +12% year over year
Gross profit$10.8B 72% margin
Operating profit$4B 27% margin
Net profit$0.7B 5% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 15 100% +12%
Skyrizi 4.5 30% +31%
Neuroscience 2.9 19% +26%
Rinvoq 2.1 14% +23%
Oncology 1.6 11% +0%
Aesthetics 1.2 8% +8%
Other 1 7%
Other Key Products 1 7% +23%
Humira 0.7 5% −39%
Cost of revenue−4.228%
Gross profit10.872% margin+2pp
SG&A−3.624%−1pp
Other−3.221%+0pp
Operating profit427% margin−1pp
Tax−0.3
Interest & other costs−3
Net profit0.75%−5pp
Filing on EDGAR More quarters of ABBV

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters